UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Systematic Review on Vestibular Symptoms in Patients With Enlarged Vestibular Aqueducts

The Laryngoscope, 2022-04, Vol.132 (4), p.873-880

2022

Volltextzugriff (PDF)

Efficacy of X-ray in the diagnosis of pediatric nasal fracture

International journal of pediatric otorhinolaryngology, 2022-11, Vol.162, p.111305-111305, Article 111305

2022

Volltextzugriff (PDF)

Development and Interrater Agreement of a Novel Classification System Combining Medical and Surgical Adverse Event Reporting

JAMA otolaryngology-- head & neck surgery, 2023-05, Vol.149 (5), p.424

2023

Volltextzugriff (PDF)

Bend but don't break: Experience of a diverse New York City lung cancer screening program during the first year of the COVID-19 pandemic

Clinical imaging, 2023-08, Vol.100, p.1-6

2023

Volltextzugriff (PDF)

Hearing loss patterns in enlarged vestibular aqueduct syndrome: Do fluctuations have clinical significance?

International journal of pediatric otorhinolaryngology, 2022-05, Vol.156, p.111072-111072, Article 111072

2022

Volltextzugriff (PDF)

Imaging Indicators of High KI-67 Proliferation Index in Pituitary Macroadenomas

Journal of Neurological Surgery Part B: Skull Base, 2022, Vol.83 (S 01)

2022

Volltextzugriff (PDF)

Novel, bilateral, two-bellied muscles span the extensor forearm, thenar eminence to insert on the proximal phalanx of the thumb: clinical and embryological significance

Folia morphologica, 2020-01, Vol.79 (1), p.182-187

2020

Volltextzugriff (PDF)

Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age

Blood reviews, 2023-05, Vol.59, p.101033-101033, Article 101033

2023

Volltextzugriff (PDF)

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Blood, 2023-11, Vol.142 (Supplement 1), p.977-977

2023

Volltextzugriff (PDF)

Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?

Acta haematologica, 2024, Vol.147 (2), p.122-132

2024

Volltextzugriff (PDF)

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Blood, 2023-11, Vol.142 (Supplement 1), p.2319-2319

2023

Volltextzugriff (PDF)

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood, 2023-11, Vol.142 (Supplement 1), p.1549-1549

2023

Volltextzugriff (PDF)

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Blood advances, 2021-03, Vol.5 (5), p.1552-1564

2021

Volltextzugriff (PDF)

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

Leukemia, 2024-07, Vol.38 (7), p.1494-1500

2024

Volltextzugriff (PDF)

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Blood, 2022-11, Vol.140 (Supplement 1), p.8938-8939

2022

Volltextzugriff (PDF)

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3084-3084

2024

Volltextzugriff (PDF)

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

Leukemia, 2024-04, Vol.38 (4), p.762-768

2024

Volltextzugriff (PDF)

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1478-1478

2023

Volltextzugriff (PDF)

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood, 2023-11, Vol.142 (Supplement 1), p.1589-1589

2023

Volltextzugriff (PDF)

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood, 2023-11, Vol.142 (Supplement 1), p.2964-2964

2023

Volltextzugriff (PDF)

Mapping genotypes to chromatin accessibility profiles in single cells

Nature (London), 2024-05, Vol.629 (8014), p.1149-1157

2024

Volltextzugriff (PDF)

Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

American journal of hematology, 2022-01, Vol.97 (1), p.E7-E10

2022

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Systematic Review on Vestibular Symptoms in Patients With Enlarged Vestibular Aqueducts

Efficacy of X-ray in the diagnosis of pediatric nasal fracture

Development and Interrater Agreement of a Novel Classification System Combining Medical and Surgical Adverse Event Reporting

Bend but don't break: Experience of a diverse New York City lung cancer screening program during the first year of the COVID-19 pandemic

Hearing loss patterns in enlarged vestibular aqueduct syndrome: Do fluctuations have clinical significance?

Imaging Indicators of High KI-67 Proliferation Index in Pituitary Macroadenomas

Novel, bilateral, two-bellied muscles span the extensor forearm, thenar eminence to insert on the proximal phalanx of the thumb: clinical and embryological significance

Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age

Prognostic impact of ‘multi-hit’ versus ‘single hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases

Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax

Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?

Evaluating Inpatient Care Team Models in Hematology and Oncology Fellowship Programs in the United States

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Mapping genotypes to chromatin accessibility profiles in single cells

Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Suchergebnisse filtern